secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001558370-25-002702
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Therapeutics Q4 2024 net loss $34.5M; tau gene therapy VY1706 IND filing planned for 2026
--------------------------------------------------------------------------------

- Net loss $34.5M in Q4 2024 vs net income $56.4M in Q4 2023; full year net loss $65.0M vs income $132.3M.
- Collaboration revenue $6.3M in Q4 2024 vs $90.1M in Q4 2023; $80.0M full year vs $250.0M in 2023.
- Cash and marketable securities $332.4M as of Dec 31, 2024; runway extended into mid-2027 excluding milestones.
- Tau silencing gene therapy VY1706 reduced tau mRNA 50-73% in NHP study; IND filing anticipated in 2026.
- Anti-tau antibody VY7523 MAD study initiated; initial tau PET data in Alzheimer's patients expected H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000155837025002702/0001558370-25-002702-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000155837025002702/vygr-20250311x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-002702

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer